Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.

President Donald Trump began his second administration with a blitz of policy actions to reorient U.S. government priorities.

An economy expert says short term, senior citizens will continue to carry the high costs of prescription drugs. but President Trump's long-term action could benefit the economy and eventually drive those prices down. 76-year-old Deana Deck is on a fixed income which makes affordable prescriptions a necessity.

Only Congress can repeal parts of the Inflation Reduction Act that now lets Medicare negotiate drug prices. Still, some are worried cuts could come that hurt seniors and people wi

President Trump is rolling back Biden healthcare policies, such as expansions to the Affordable Care Act – a move Democrats described as an "attack" on the federal program.

About half of respondents said the nation should spend more on Medicaid and Medicare — a potential challenge for the Trump administration looking to cut costs.

The Democratic National Committee ( DNC) is going on the offense against President Donald Trump just two days into his second term, blasting the 45th and 47th President over what they say is a plan to follow through on the controversial Project 2025 agenda, including by cutting Social Security, Medicare and Medicaid.

Funding cuts and regulatory changes could radically reduce Medicaid, the largest program providing medical and health-related services to low-income people, as well as Medicare, federal health insurance for people 65 or older, and some under 65 with certain disabilities or conditions.

U.S. President Donald Trump is pushing a plan to explicitly use revenue from higher tariffs on imported goods to help pay for extending trillions of dollars in tax cuts, an unprecedented shift likely to face opposition from many of his fellow Republicans in Congress.

Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.

The first major legislative win for this issue came in 2022 when the NO PAIN Act was signed into law. By providing separate Medicare reimbursement for non-opioid therapies, this bill expanded patient and provider access to FDA-approved non-opioids in all outpatient surgical settings.